{"transactions":[{"id":4626937,"issuer":{"id":1723,"kind":"organization","name":"Stoke Therapeutics, Inc.","symbol":"STOK"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-25T20:12:39.000Z","date":"2026-09-23","kind":"grant","planned":false,"acquired":true,"shares":39674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest as to 1/12th of the total award quarterly on the 23rd calendar day of each December, March, June, and September, with the first tranche vesting on December 23, 2026, subject to the reporting person's continued service to the Issuer through each vesting date."}],"balance_after":39674,"derivative":{"exercise_price":26.11,"expiration_date":"2036-09-22","underlying":"Common Stock","underlying_shares":39674},"source":{"system":"sec-edgar","filing":"0001685994-26-000009","document":"form4-09252026_080935.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000168599426000009/form4-09252026_080935.xml","form_type":"4"}},{"id":740067,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-13T00:40:49.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":56345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":56345,"derivative":{"exercise_price":14.09,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":56345},"source":{"system":"sec-edgar","filing":"0001193125-26-269997","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269997/ownership.xml","form_type":"4"}},{"id":746197,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T18:34:47.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date."}],"balance_after":40000,"derivative":{"exercise_price":10.55,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-262281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000119312526262281/ownership.xml","form_type":"4"}},{"id":803728,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-04-21T20:05:07.000Z","date":"2026-01-29","kind":"grant","planned":true,"acquired":true,"shares":169401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units (\"PSUs\") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board (\"Performance Milestones\"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units (\"PSUs\") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board (\"Performance Milestones\"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027."}],"balance_after":169401,"derivative":{"underlying":"Common Stock","underlying_shares":169401},"source":{"system":"sec-edgar","filing":"0001193125-26-166735","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526166735/ownership.xml","form_type":"4"}},{"id":896929,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-19T02:38:15.000Z","date":"2026-02-13","kind":"exercise","planned":true,"acquired":false,"shares":30031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on February 13, 2024 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on February 13, 2024 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":60063,"derivative":{"underlying":"Common Stock","underlying_shares":30301},"source":{"system":"sec-edgar","filing":"0001193125-26-057878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526057878/ownership.xml","form_type":"4"}},{"id":896928,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-19T02:38:15.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":16644,"price":5.8233,"value":96923.0052,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form."}],"balance_after":235405,"source":{"system":"sec-edgar","filing":"0001193125-26-057878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526057878/ownership.xml","form_type":"4"}},{"id":896927,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-19T02:38:15.000Z","date":"2026-02-13","kind":"exercise","planned":true,"acquired":true,"shares":30031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."}],"balance_after":252049,"source":{"system":"sec-edgar","filing":"0001193125-26-057878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526057878/ownership.xml","form_type":"4"}},{"id":916053,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-06T23:01:54.000Z","date":"2026-02-04","kind":"sale","planned":true,"acquired":false,"shares":48913,"price":6.4419,"value":315092.6547,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form."}],"balance_after":222018,"source":{"system":"sec-edgar","filing":"0001193125-26-041519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526041519/ownership.xml","form_type":"4"}},{"id":925152,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-31","kind":"exercise","planned":true,"acquired":false,"shares":100400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSUs\") converts to common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On January 31, 2025 (the \"2025 Grant Date\"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On January 31, 2025 (the \"2025 Grant Date\"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary."}],"balance_after":301200,"derivative":{"underlying":"Common Stock","underlying_shares":100400},"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925151,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-29","kind":"grant","planned":true,"acquired":true,"shares":254900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSUs\") converts to common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary."}],"balance_after":254900,"derivative":{"underlying":"Common Stock","underlying_shares":254900},"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925150,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-29","kind":"grant","planned":true,"acquired":true,"shares":509850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary."}],"balance_after":509850,"derivative":{"exercise_price":6.6,"expiration_date":"2036-01-29","underlying":"Common Stock","underlying_shares":509850},"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925149,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Stock Units","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":false,"shares":169401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSUs\") converts to common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board (\"Performance Milestones\"), subject to the grantee's continued service with the Company (the \"Approval Conditions\"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the \"2026 Grant Date\") resulting in the vesting of the PSUs as to 25% of the underlying shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board (\"Performance Milestones\"), subject to the grantee's continued service with the Company (the \"Approval Conditions\"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the \"2026 Grant Date\") resulting in the vesting of the PSUs as to 25% of the underlying shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":169401},"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925148,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T01:16:31.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":80258,"price":6.4369,"value":516612.7202,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form."}],"balance_after":270931,"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925147,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-31","kind":"exercise","planned":true,"acquired":true,"shares":100400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSUs\") converts to common stock on a one-for-one basis."}],"balance_after":351189,"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":925146,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T01:16:31.000Z","date":"2026-01-29","kind":"exercise","planned":true,"acquired":true,"shares":169401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance stock unit (\"PSUs\") converts to common stock on a one-for-one basis."}],"balance_after":250789,"source":{"system":"sec-edgar","filing":"0001193125-26-034087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526034087/ownership.xml","form_type":"4"}},{"id":980328,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-12-04T21:20:35.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":false,"shares":28612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":28613,"derivative":{"underlying":"Common Stock","underlying_shares":28612},"source":{"system":"sec-edgar","filing":"0001193125-25-308115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525308115/ownership.xml","form_type":"4"}},{"id":980327,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-04T21:20:35.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":10808,"price":5.11,"value":55228.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo."}],"balance_after":81388,"source":{"system":"sec-edgar","filing":"0001193125-25-308115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525308115/ownership.xml","form_type":"4"}},{"id":980326,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-04T21:20:35.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":true,"shares":28612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,866 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025."}],"balance_after":92196,"source":{"system":"sec-edgar","filing":"0001193125-25-308115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525308115/ownership.xml","form_type":"4"}},{"id":1063972,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-08-18T20:10:23.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the \"Grant Date\") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the \"Grant Date\") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary."}],"balance_after":168750,"derivative":{"underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0000950170-25-109723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025109723/ownership.xml","form_type":"4"}},{"id":1063971,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-08-18T20:10:23.000Z","date":"2025-08-14","kind":"grant","planned":false,"acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the \"Grant Date\") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary."}],"balance_after":337500,"derivative":{"exercise_price":6.17,"expiration_date":"2035-08-14","underlying":"Common Stock","underlying_shares":337500},"source":{"system":"sec-edgar","filing":"0000950170-25-109723","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025109723/ownership.xml","form_type":"4"}},{"id":1080669,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:04.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.73,"underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-099251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099251/ownership.xml","form_type":"4"}},{"id":1080668,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-28T17:15:04.000Z","date":"2025-07-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":136139,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of an Agreement and Plan of Merger, dated as of June 16, 2025, by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation, at the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of Issuer having an exercise price less than $10.50 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\") (each such option, a \"Cash-Out Stock Option\") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(continued from footnote 1) applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one non-tradeable contingent value right for each share subject to such Cash-Out Stock Option (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":5.02,"underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-25-099251","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025099251/ownership.xml","form_type":"4"}},{"id":1084753,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-18T21:14:07.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth of the shares subject to the option shall vest and become exercisable on August 16, 2025 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":2.12,"expiration_date":"2035-07-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-25-020022","document":"form4-07182025_090703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925020022/form4-07182025_090703.xml","form_type":"4"}},{"id":1119865,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T17:01:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":42200,"derivative":{"exercise_price":5.73,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42200},"source":{"system":"sec-edgar","filing":"0000950170-25-083234","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017025083234/ownership.xml","form_type":"4"}},{"id":1121308,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T16:11:33.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date."}],"balance_after":40000,"derivative":{"exercise_price":1.29,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-25-082324","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000095017025082324/ownership.xml","form_type":"4"}},{"id":1186477,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-01T16:19:03.000Z","date":"2025-03-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option vest in equal monthly installments from March 28, 2025 (the \"Vesting Commencement Date\") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":80000,"derivative":{"exercise_price":1.28,"expiration_date":"2035-03-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-048549","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000095017025048549/ownership.xml","form_type":"4"}},{"id":1263830,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T21:05:04.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":false,"shares":30031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on February 13, 2024 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on February 13, 2024 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":90094,"derivative":{"underlying":"Common Stock","underlying_shares":30301},"source":{"system":"sec-edgar","filing":"0000950170-25-022200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025022200/ownership.xml","form_type":"4"}},{"id":1263829,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-18T21:05:04.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":11365,"price":3.96,"value":45005.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo."}],"balance_after":60717,"source":{"system":"sec-edgar","filing":"0000950170-25-022200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025022200/ownership.xml","form_type":"4"}},{"id":1263828,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-18T21:05:04.000Z","date":"2025-02-13","kind":"exercise","planned":true,"acquired":true,"shares":30031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."}],"balance_after":72082,"source":{"system":"sec-edgar","filing":"0000950170-25-022200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025022200/ownership.xml","form_type":"4"}},{"id":1274054,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-11T21:38:08.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":401600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on the January 31, 2025 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on the January 31, 2025 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":401600,"derivative":{"underlying":"Common Stock","underlying_shares":401600},"source":{"system":"sec-edgar","filing":"0000950170-25-017959","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017025017959/ownership.xml","form_type":"4"}},{"id":1342981,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-12-04T22:27:13.000Z","date":"2024-12-02","kind":"exercise","planned":false,"acquired":false,"shares":28612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":57225,"derivative":{"underlying":"Common Stock","underlying_shares":28612},"source":{"system":"sec-edgar","filing":"0000950170-24-133360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024133360/ownership.xml","form_type":"4"}},{"id":1342980,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-04T22:27:13.000Z","date":"2024-12-03","kind":"sale","planned":false,"acquired":false,"shares":11114,"price":5.5998,"value":62236.1772,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Mr. Cumbo."}],"balance_after":38484,"source":{"system":"sec-edgar","filing":"0000950170-24-133360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024133360/ownership.xml","form_type":"4"}},{"id":1342979,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-04T22:27:13.000Z","date":"2024-12-02","kind":"exercise","planned":false,"acquired":true,"shares":28612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,547 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024."}],"balance_after":49598,"source":{"system":"sec-edgar","filing":"0000950170-24-133360","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024133360/ownership.xml","form_type":"4"}},{"id":1467320,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-28T07:45:09.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":136139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":136139,"derivative":{"exercise_price":5.02,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":136139},"source":{"system":"sec-edgar","filing":"0000950170-24-078783","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000095017024078783/ownership.xml","form_type":"4"}},{"id":1638326,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T17:01:20.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":120125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":120125,"derivative":{"underlying":"Common Stock","underlying_shares":120125},"source":{"system":"sec-edgar","filing":"0000950170-24-016219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024016219/ownership.xml","form_type":"4"}},{"id":1638325,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-02-16T17:01:20.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":240250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 13, 2024 (the \"Grant Date\") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary."}],"balance_after":240250,"derivative":{"exercise_price":7.85,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":240250},"source":{"system":"sec-edgar","filing":"0000950170-24-016219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017024016219/ownership.xml","form_type":"4"}},{"id":1721784,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-12-05T19:40:13.000Z","date":"2023-12-02","kind":"exercise","planned":false,"acquired":false,"shares":28612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on December 2, 2022 (the \"Grant Date\") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":85837,"derivative":{"underlying":"Common Stock","underlying_shares":28612},"source":{"system":"sec-edgar","filing":"0000950170-23-068076","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017023068076/ownership.xml","form_type":"4"}},{"id":1721783,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-05T19:40:13.000Z","date":"2023-12-04","kind":"sale","planned":false,"acquired":false,"shares":11757,"price":2.7657,"value":32516.3349,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1)."}],"balance_after":17439,"source":{"system":"sec-edgar","filing":"0000950170-23-068076","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017023068076/ownership.xml","form_type":"4"}},{"id":1721782,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-05T19:40:13.000Z","date":"2023-12-02","kind":"exercise","planned":false,"acquired":true,"shares":28612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the \"RSUs\")."}],"balance_after":29196,"source":{"system":"sec-edgar","filing":"0000950170-23-068076","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000095017023068076/ownership.xml","form_type":"4"}},{"id":1849765,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T17:00:18.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":26642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the \"Vesting Commencement Date\") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director."}],"balance_after":26642,"derivative":{"exercise_price":19.84,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":26642},"source":{"system":"sec-edgar","filing":"0001209191-23-038471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919123038471/doc4.xml","form_type":"4"}},{"id":2096190,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2022-12-05T22:46:45.000Z","date":"2022-12-02","kind":"grant","acquired":true,"shares":114449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the \"RSUs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary."}],"balance_after":114449,"derivative":{"underlying":"Common Stock","underlying_shares":114449},"source":{"system":"sec-edgar","filing":"0000899243-22-037681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322037681/doc4.xml","form_type":"4"}},{"id":2096189,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-05T22:46:45.000Z","date":"2022-12-02","kind":"grant","acquired":true,"shares":228900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on December 2, 2022 (the \"Grant Date\") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary."}],"balance_after":228900,"derivative":{"exercise_price":6.77,"expiration_date":"2032-12-02","underlying":"Common Stock","underlying_shares":228900},"source":{"system":"sec-edgar","filing":"0000899243-22-037681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322037681/doc4.xml","form_type":"4"}},{"id":2096188,"issuer":{"id":4915,"kind":"organization","name":"Solid Biosciences Inc.","symbol":"SLDB"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-05T22:46:45.000Z","date":"2022-12-02","kind":"grant","acquired":true,"shares":584,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person acquired 584 shares of the issuer's common stock pursuant to the issuer's acquisition of all of the outstanding capital stock of AavantiBio, Inc. on December 2, 2022."}],"balance_after":584,"source":{"system":"sec-edgar","filing":"0000899243-22-037681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1707502/000089924322037681/doc4.xml","form_type":"4"}},{"id":2234309,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T17:00:54.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through June 9, 2025, subject to the Reporting Person's continued service."}],"balance_after":31000,"derivative":{"exercise_price":14.04,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001209191-22-036370","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919122036370/doc4.xml","form_type":"4"}},{"id":3183417,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:01:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":12.99,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-20-042768","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000110465920042768/a4.xml","form_type":"4"}},{"id":3183416,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:01:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":19.88,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-042768","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000110465920042768/a4.xml","form_type":"4"}},{"id":3242221,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-29T01:01:37.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and\nbecome exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of\nthe date of grant."}],"balance_after":37500,"derivative":{"exercise_price":114.47,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-20-014226","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014226/doc4.xml","form_type":"4"}},{"id":3242220,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-02-29T01:01:37.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":6700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of\nthe shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25%\nwill vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the\nfourth anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. 25% of\nthe shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25%\nwill vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the\nfourth anniversary of the grant date."}],"balance_after":8567,"source":{"system":"sec-edgar","filing":"0001209191-20-014226","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014226/doc4.xml","form_type":"4"}},{"id":3339793,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":26084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":20881,"derivative":{"exercise_price":26.24,"exercise_date":"2014-01-02","expiration_date":"2023-01-02","underlying":"Common Stock","underlying_shares":26084},"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339792,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":3895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":0,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":3895},"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339791,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":false,"shares":2727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":1123,"derivative":{"exercise_price":13.71,"exercise_date":"2016-09-09","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":2727},"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339790,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"sale","acquired":false,"shares":9294,"price":125.5,"value":1166397.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":1867,"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339789,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"sale","acquired":false,"shares":32706,"price":125.5,"value":4104603.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":11161,"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339788,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":26084,"price":26.24,"value":684444.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":43867,"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339787,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":3895,"price":13.71,"value":53400.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":17783,"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3339786,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-12-18T01:02:14.000Z","date":"2019-12-13","kind":"exercise","acquired":true,"shares":2727,"price":13.71,"value":37387.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":13888,"source":{"system":"sec-edgar","filing":"0001209191-19-061050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119061050/doc4.xml","form_type":"4"}},{"id":3491448,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-06-13T16:35:47.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 11, 2019, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the first anniversary of the grant date of June 11, 2019 or (ii) the Issuer's annual meeting of shareholders in 2020."}],"balance_after":15000,"derivative":{"exercise_price":19.88,"expiration_date":"2029-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-035366","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000110465919035366/a4.xml","form_type":"4"}},{"id":3574427,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-29T23:59:46.000Z","date":"2019-03-28","kind":"tax_withholding","acquired":false,"shares":2165,"price":118.68,"value":256942.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock units."}],"balance_after":11161,"source":{"system":"sec-edgar","filing":"0001209191-19-021875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119021875/doc4.xml","form_type":"4"}},{"id":3574426,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-29T23:59:46.000Z","date":"2019-03-28","kind":"grant","acquired":true,"shares":4876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reflects the vesting of previously granted performance-based restricted stock units."}],"balance_after":13326,"source":{"system":"sec-edgar","filing":"0001209191-19-021875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119021875/doc4.xml","form_type":"4"}},{"id":3620937,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T01:06:57.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":45000,"derivative":{"exercise_price":145.48,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-016038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119016038/doc4.xml","form_type":"4"}},{"id":3620936,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-03-05T01:06:57.000Z","date":"2019-02-28","kind":"disposition_to_issuer","acquired":false,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Forfeiture of 3,375 shares of restricted stock due to performance goal not met."}],"balance_after":8450,"source":{"system":"sec-edgar","filing":"0001209191-19-016038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119016038/doc4.xml","form_type":"4"}},{"id":3680393,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-02T01:27:34.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":46965,"derivative":{"exercise_price":26.24,"exercise_date":"2014-01-02","expiration_date":"2023-01-02","underlying":"Common Stock","underlying_shares":5250},"source":{"system":"sec-edgar","filing":"0001209191-19-006634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119006634/doc4.xml","form_type":"4"}},{"id":3680392,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-02T01:27:34.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":0,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001209191-19-006634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119006634/doc4.xml","form_type":"4"}},{"id":3680391,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-02T01:27:34.000Z","date":"2019-02-01","kind":"sale","acquired":false,"shares":15000,"price":140,"value":2100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":15266,"source":{"system":"sec-edgar","filing":"0001209191-19-006634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119006634/doc4.xml","form_type":"4"}},{"id":3680390,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-02T01:27:34.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":5250,"price":26.24,"value":137760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":30266,"source":{"system":"sec-edgar","filing":"0001209191-19-006634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119006634/doc4.xml","form_type":"4"}},{"id":3680389,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2019-02-02T01:27:34.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":2250,"price":13.9,"value":31275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":25016,"source":{"system":"sec-edgar","filing":"0001209191-19-006634","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119006634/doc4.xml","form_type":"4"}},{"id":3763310,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-11-15T16:34:42.000Z","date":"2018-11-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 14, 2018, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock. The option will vest and become exercisable in three equal installments on each of November 14, 2019, November 14, 2020 and November 14, 2021."}],"balance_after":25000,"derivative":{"exercise_price":12.99,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-18-068789","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1685994/000110465918068789/a4.xml","form_type":"4"}},{"id":3850113,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-08-08T22:16:16.000Z","date":"2018-08-08","kind":"tax_withholding","acquired":false,"shares":6000,"price":121.02,"value":726120.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock award granted on September 19, 2016."}],"balance_after":22766,"source":{"system":"sec-edgar","filing":"0001209191-18-045907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118045907/doc4.xml","form_type":"4"}},{"id":3869682,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":false,"shares":11914,"price":13.9,"value":165604.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":2250,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":11914},"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869681,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":false,"shares":9944,"price":13.71,"value":136332.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":3895,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":9944},"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869680,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":false,"shares":11924,"price":13.71,"value":163478.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":3850,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":11924},"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869679,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"sale","acquired":false,"shares":11914,"price":137.32,"value":1636030.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":28766,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869678,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":11914,"price":13.9,"value":165604.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":40680,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869677,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"sale","acquired":false,"shares":9944,"price":137.32,"value":1365510.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":28766,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869676,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":9944,"price":13.71,"value":136332.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":38710,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869675,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"sale","acquired":false,"shares":11924,"price":137.32,"value":1637403.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":28766,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3869674,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-07-11T22:05:24.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":11924,"price":13.71,"value":163478.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 8, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":40690,"source":{"system":"sec-edgar","filing":"0001209191-18-042389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118042389/doc4.xml","form_type":"4"}},{"id":3919466,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-05-24T22:04:22.000Z","date":"2018-05-22","kind":"exercise","acquired":false,"shares":4876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4876},"source":{"system":"sec-edgar","filing":"0001209191-18-033108","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033108/doc4.xml","form_type":"4"}},{"id":3919465,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-05-24T22:04:22.000Z","date":"2018-05-22","kind":"tax_withholding","acquired":false,"shares":1435,"price":89.22,"value":128030.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017."}],"balance_after":28766,"source":{"system":"sec-edgar","filing":"0001209191-18-033108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033108/doc4.xml","form_type":"4"}},{"id":3919464,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-05-24T22:04:22.000Z","date":"2018-05-22","kind":"exercise","acquired":true,"shares":4876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":30201,"source":{"system":"sec-edgar","filing":"0001209191-18-033108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118033108/doc4.xml","form_type":"4"}},{"id":3993685,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":1370,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11415,"derivative":{"exercise_price":26.24,"exercise_date":"2014-01-02","expiration_date":"2023-01-02","underlying":"Common Stock","underlying_shares":1370},"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993684,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":835,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5001,"derivative":{"exercise_price":13.9,"exercise_date":"2016-02-27","expiration_date":"2025-02-27","underlying":"Common Stock","underlying_shares":835},"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993683,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":54,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6107,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":54},"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993682,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":false,"shares":241,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1485,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":241},"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993681,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":442,"price":81.22,"value":35899.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":25325,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993680,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":1370,"price":26.24,"value":35948.8,"ownership":{"direct":true},"balance_after":25767,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993679,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":142,"price":81.22,"value":11533.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":24397,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993678,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":835,"price":13.9,"value":11606.5,"ownership":{"direct":true},"balance_after":24539,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993677,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":9,"price":81.22,"value":730.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":23704,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993676,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":54,"price":13.71,"value":740.34,"ownership":{"direct":true},"balance_after":23713,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993675,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"tax_withholding","acquired":false,"shares":40,"price":81.22,"value":3248.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an \"option swap\" enables the exercise and holding of shares of Common Stock by the Reporting Person."}],"balance_after":23659,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":3993674,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2018-03-16T22:10:55.000Z","date":"2018-03-15","kind":"exercise","acquired":true,"shares":241,"price":13.71,"value":3304.11,"ownership":{"direct":true},"balance_after":23699,"source":{"system":"sec-edgar","filing":"0001209191-18-020351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118020351/doc4.xml","form_type":"4"}},{"id":4009162,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-03-07T23:03:27.000Z","date":"2018-03-05","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant."}],"balance_after":70000,"derivative":{"exercise_price":71.45,"expiration_date":"2028-03-05","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-017790","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118017790/doc4.xml","form_type":"4"}},{"id":4241803,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2017-08-07T20:38:32.000Z","date":"2017-08-03","kind":"exercise","acquired":false,"shares":9752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9752},"source":{"system":"sec-edgar","filing":"0001209191-17-047895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047895/doc4.xml","form_type":"4"}},{"id":4241802,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-08-07T20:38:32.000Z","date":"2017-08-03","kind":"tax_withholding","acquired":false,"shares":3169,"price":37.88,"value":120041.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017."}],"balance_after":23458,"source":{"system":"sec-edgar","filing":"0001209191-17-047895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047895/doc4.xml","form_type":"4"}},{"id":4241801,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-08-07T20:38:32.000Z","date":"2017-08-03","kind":"exercise","acquired":true,"shares":9752,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":26627,"source":{"system":"sec-edgar","filing":"0001209191-17-047895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117047895/doc4.xml","form_type":"4"}},{"id":4253530,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2017-07-22T01:45:59.000Z","date":"2017-07-20","kind":"exercise","acquired":false,"shares":2500,"price":13.71,"value":34275.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":15774,"derivative":{"exercise_price":13.71,"exercise_date":"2017-02-28","expiration_date":"2026-02-28","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-17-046035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046035/doc4.xml","form_type":"4"}},{"id":4253529,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-07-22T01:45:59.000Z","date":"2017-07-20","kind":"sale","acquired":false,"shares":3418,"price":41,"value":140138.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":16875,"source":{"system":"sec-edgar","filing":"0001209191-17-046035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046035/doc4.xml","form_type":"4"}},{"id":4253528,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-07-22T01:45:59.000Z","date":"2017-07-20","kind":"sale","acquired":false,"shares":2500,"price":41,"value":102500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":20293,"source":{"system":"sec-edgar","filing":"0001209191-17-046035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046035/doc4.xml","form_type":"4"}},{"id":4253527,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":38786,"kind":"person","name":"Cumbo Alexander","position":1,"cik":"0001685994","reported_name":"Cumbo Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2017-07-22T01:45:59.000Z","date":"2017-07-20","kind":"exercise","acquired":true,"shares":2500,"price":13.71,"value":34275.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 15, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction."}],"balance_after":22793,"source":{"system":"sec-edgar","filing":"0001209191-17-046035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919117046035/doc4.xml","form_type":"4"}}],"next_cursor":"2017-07-22T01:45:59.000000Z,4253527"}